Stephanie Davis
Stock Analyst at Barclays
(1.25)
# 3,308
Out of 4,829 analysts
95
Total ratings
33.85%
Success rate
-12.1%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $176.96 | +4.54% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $40.01 | +12.47% | 3 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $9.99 | -49.95% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $59.19 | +26.71% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.73 | +22.16% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.32 | +38.89% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.05 | +109.94% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $283.00 | +2.47% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $23.07 | +4.03% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $148.22 | -10.27% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $25.78 | +124.98% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.02 | -0.66% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.37 | +102.70% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $245.73 | +1.33% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $25.62 | +13.19% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.11 | +378.20% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.19 | +60.45% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $237.05 | -1.71% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $4.13 | +311.62% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $90.44 | -15.97% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $176.96
Upside: +4.54%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $40.01
Upside: +12.47%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $9.99
Upside: -49.95%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $59.19
Upside: +26.71%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.73
Upside: +22.16%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.32
Upside: +38.89%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.05
Upside: +109.94%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $283.00
Upside: +2.47%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $23.07
Upside: +4.03%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $148.22
Upside: -10.27%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $25.78
Upside: +124.98%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.02
Upside: -0.66%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.37
Upside: +102.70%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $245.73
Upside: +1.33%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $25.62
Upside: +13.19%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $7.11
Upside: +378.20%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.19
Upside: +60.45%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $237.05
Upside: -1.71%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $4.13
Upside: +311.62%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $90.44
Upside: -15.97%